Accumulating neurological disability has a substantial impact on the lives of patients with
multiple sclerosis (MS). As well as the established Expanded Disability Status Scale (EDSS) …

Introduction Ozanimod is a selective sphingosine 1-phosphate receptor 1 and 5 modulator
under development by Celgene, for the treatment of relapsing remitting multiple sclerosis …

Objective Primary progressive multiple sclerosis (PPMS) does not respond well to
immunomodulatory or immunosuppressive treatment. Chronic activation of microglia has …

Background: Preclinical studies suggest that fluoxetine has neuroprotective properties that
might reduce axonal degeneration in multiple sclerosis (MS). Objective: To determine …

In the past two decades, monoclonal antibodies (mAbs) have revolutionized the treatment of
multiple sclerosis (MS). However, a remarkable number of mAbs failed due to negative study …

Upon the approval of disease-modifying therapies (DMTs) for patients with active secondary
progressive phase of multiple sclerosis (SPMS), there became an emerging need to …

Objective Progression prediction is a significant unmet need in people with progressive
multiple sclerosis (pwPMS). Studies on glial fibrillary acidic protein (GFAP) have either been …

Background Clinical trials in primary progressive MS (PPMS) generally use the Expanded
Disability Status Scale (EDSS) as their primary outcome measure, although different clinical …

Background: The research is focused on sensitive biomarkers in multiple sclerosis (MS).
Objective: The aim of the study was to assess the relationship between plasma …

Objectives Detection and prediction of disability progression is a significant unmet need in
people with progressive multiple sclerosis (PwPMS). Government and health agencies have …